A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.

被引：0
|
作者：
Di Giacomo, Anna Maria
Annesi, Diego
Ascierto, Paolo Antonio
Calabro, Luana
Chiarion-Sileni, Vanna
Danielli, Riccardo
Del Vecchio, Michele
Ferraresi, Virginia
Ferrucci, Pier Francesco
Fonsatti, Ester
Guida, Michele
Giannarelli, Diana
Guidoboni, Massimo
Mandala, Mario
Quaglino, Pietro
Queirolo, Paola
Maccalli, Cristina
Parmiani, Giorgio
Maio, Michele
机构：
[1] Univ Hosp Siena, Med Oncol & Immunotherapy, Siena, Italy
[2] Univ Hosp Siena, Siena, Italy
[3] Ist Nazl Tumori IRCCS, Naples, Italy
[4] Veneto Oncol Inst, Padua, Italy
[5] Azienda Osped Senese, Siena, Italy
[6] Ist Nazl Tumori, I-20133 Milan, Italy
[7] Regina Elena Inst Canc Res, Rome, Italy
[8] European Inst Oncol, Milan, Italy
[9] Ist Oncol, Bari, BA, Italy
[10] IRCCS IRST, Immunotherapy & Somat Cell Therapy Lab, Meldola, Italy
[11] Papa Giovanni XIII Hosp, Bergamo, Italy
[12] Univ Turin, Dermatol Clin, Dept Med Sci, Turin, Italy
[13] Natl Inst Canc Res, Genoa, Italy
[14] Italian Network Tumor Biotherapy Lab, Siena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9090
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with melanoma with brain metastasis: The NIBIT-M2 study
    Di Giacomo, A. M.
    Maio, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 5 - 5
  • [2] Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
    Di Giacomo, A. M.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Ferrucci, P. F.
    Guida, M.
    Quaglino, P.
    Guidoboni, M.
    Marchetti, P.
    Cutaia, O.
    Amato, G.
    Gambale, E.
    Calabro, L.
    Valente, M.
    Danielli, R.
    Giannarelli, D.
    Mandala, M.
    Maio, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S734 - S734
  • [3] A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.
    Di Giacomo, A. M.
    Ascierto, P. A.
    Fonsatti, E.
    Pittiglio, E.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Parmiani, G.
    Maio, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial
    Di Giacomo, A. M.
    Ascierto, P. A.
    Pittiglio, E.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Parmiani, G.
    Maio, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S653 - S654
  • [5] The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases
    Maio, Michele
    Testori, Alessandro
    Ascierto, Paolo Antonio
    Ridolfi, Ruggero
    Santinami, Mario
    Pilla, Lorenzo
    Queirolo, Paola
    Grosso, Marco
    Simeone, Ester
    Vittoria, Stefania
    Nicoletti, Luisa
    Rivoltini, Licia
    Ferrucci, Pier Francesco
    Parmiani, Giorgio
    Di Giacomo, Anna Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.
    Di Giacomo, Anna Maria
    Ascierto, Paolo Antonio
    Pilla, Lorenzo
    Ridolfi, Ruggero
    Santinami, Mario
    Testori, Alessandro
    Queirolo, Paola
    Simeone, Ester
    Guidoboni, Massimo
    Del Vecchio, Michele
    Ferrucci, Pier Francesco
    Marasco, Antonella
    Fonsatti, Ester
    Annesi, Diego
    Giannarelli, Diana
    Parmiani, Giorgio
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] The Italian Network for Tumor Biotherapy (NIBIT)-M1 study: 2-years survival update for metastatic melanoma patients treated with ipilimumab in combination with fotemustine
    Di Giacomo, A. M.
    Ascierto, P. A.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Giannarelli, D.
    Parmiani, G.
    Maio, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [8] Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
    Di Giacomo, Anna Maria
    Ascierto, Paolo A.
    Pilla, Lorenzo
    Santinami, Mario
    Ferrucci, Pier Francesco
    Giannarelli, Diana
    Marasco, Antonella
    Rivoltini, Licia
    Simeone, Ester
    Nicoletti, Stefania V. L.
    Fonsatti, Ester
    Annesi, Diego
    Queirolo, Paola
    Testori, Alessandro
    Ridolfi, Ruggero
    Parmiani, Giorgio
    Maio, Michele
    LANCET ONCOLOGY, 2012, 13 (09): : 879 - 886
  • [9] Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
    Di Giacomo, A. M.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Ferrucci, P. F.
    Guida, M.
    Quaglino, P.
    Guidoboni, M.
    Marchetti, P.
    Simonetti, E.
    Amato, G.
    Covre, A.
    Camerini, R.
    Calabro, L.
    Valente, M.
    Mandala, M.
    Giannarelli, D.
    Maio, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S653 - S654
  • [10] Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
    Di Giacomo, Anna Maria
    Chiarion-Sileni, Vanna
    Del Vecchio, Michele
    Ferrucci, Pier Francesco
    Guida, Michele
    Quaglino, Pietro
    Guidoboni, Massimo
    Marchetti, Paolo
    Simonetti, Elena
    Santangelo, Federica
    Amato, Giovanni
    Covre, Alessia
    Camerini, Roberto
    Valente, Monica
    Mandala, Mario
    Giannarelli, Diana
    Calabro, Luana
    Maio, Michele
    EUROPEAN JOURNAL OF CANCER, 2024, 199
12345